ACRV·Nasdaq·US
Acrivon Therapeutics
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology. It develops drug candidates and companion diagnostics using its proprietary AP3 proteomics and computational platform, which is used to identify patient responders and guide clinical development.
Recent Activity
Updated Oct 24, 2026
–Acrivon is advancing ACR-7280, an optimized, AP3-enabled, potential first-in-class oral CDK11 inhibitor, toward an IND filing in the first half of 2027.
–ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models.
–Acrivon prioritized ACR-7280 from among multiple AP3-discovered, highly selective CDK11 inhibitor candidates.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.